Compare Msci Inc (MSCI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs BIO-TECHNE Corp — how do they compare? Msci Inc trades at $562.98 (market cap $45.51B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Msci Inc is far larger — about 4.1× BIO-TECHNE Corp's market cap, and Msci Inc pays the higher dividend (1.31%). Which is the better fit depends on your goals.
| MSCI | TECH | |
|---|---|---|
Market Cap | $45.51B | $11.16B |
Sector | Financials | Health |
52-Week High | $643.83 | $72.12 |
52-Week Low | $511.84 | $43.31 |
Enterprise Value | $51.67B | $11.24B |
Dividend Yield | 1.31% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
